Logan Coy Related postsA Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Mature B-Cell MalignanciesSeptember 11, 2026An Open-Label, Randomized, Controlled Phase 3 Study of Sigvotatug Vedotin with Pembrolizumab vs Pembrolizumab Monotherapy as First-Line Treatment in PD-L1 High Advanced NSCLC (BE6A LUNG-02)September 11, 2026A Phase 1/2 Open-label, Multicentre, Dose Escalation and Expansion Study of Belantamab as Monotherapy and in Combination with Other Treatments in Multiple MyelomaSeptember 11, 2026 Previous postAn Open-Label, Multicenter, Multi-Arm Phase 1 Study of ADU-1805 in Adults with Advanced Solid TumorsNext postA Phase 1/2a, Open-Label Study of SA53-OS, an MDM2 Inhibitor, in Locally Advanced or Metastatic p53 Wild-Type Solid Tumors
